Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 209 publications
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.
Journal: Future oncology (London, England)
Published: September 15, 2025
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.
Journal: Blood reviews
Published: July 25, 2025
Chimeric antigen receptor T-cell therapy for multiple myeloma.
Journal: Current opinion in oncology
Published: July 17, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
Journal: Haematologica
Published: May 21, 2025
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: May 04, 2025
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: May 04, 2025
Multifocal Colonic Masses as a Presentation of Secondary Extramedullary Plasmacytoma in Relapsing-Refractory Multiple Myeloma: A Case Report and Review of Literature.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: April 30, 2025
Quantifying Preferences for CAR-T Compared to Standard of Care as a First-Line Treatment Among Patients With Multiple Myeloma.
Journal: Cancer medicine
Published: April 21, 2025
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2025
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.
Journal: Blood cancer journal
Published: March 20, 2025
Minimal Residual Disease Negativity Rate with Isa-Kd Therapy and Its Safety in Patients with Relapsed Refractory Multiple Myeloma -A Report of 9 Cases from Real-World Clinical Practice in a Single Institution.
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: February 17, 2025
Last Updated: 10/31/2025